Science Translational Medicine · 2013 · 90 citations · 24 references
MedicineGeneticsMolecular BiologyBone MetabolismCell SignalingGene TherapyBone DevelopmentBone GrowthBone RegenerationGrowth Plate DisordersOsteogenesisSkeletal DevelopmentAbnormal Bone MineralizationFgfr3-related DisordersFibroblast Growth Factor Receptor 3 (Fgfr3) DisordersFibroblast Growth Factor Receptor SignalingIntracellular Receptor SignalingIntracellular Signaling PathwaysShort Stature GeneticsSkeletal Growth Patterns
Achondroplasia is a rare genetic disease characterized by abnormal bone development, resulting in short stature. It is caused by a single point mutation in the gene coding for fibroblast growth factor receptor 3 (FGFR3), which leads to prolonged activation upon ligand binding. To prevent excessive intracellular signaling and rescue the symptoms of achondroplasia, we have developed a recombinant protein therapeutic approach using a soluble form of human FGFR3 (sFGFR3), which acts as a decoy receptor and prevents FGF from binding to mutant FGFR3. sFGFR3 was injected subcutaneously to newborn Fgfr3(ach/+) mice-the mouse model of achondroplasia-twice per week throughout the growth period during 3 weeks. Effective maturation of growth plate chondrocytes was restored in bones of treated mice, with a dose-dependent enhancement of skeletal growth in Fgfr3(ach/+) mice. This resulted in normal stature and a significant decrease in mortality and associated complications, without any evidence of toxicity. These results describe a new approach for restoring bone growth and suggest that sFGFR3 could be a potential therapy for children with achondroplasia and related disorders.
24
Fibroblast Growth Factor Receptor 3 Is a Negative Regulator of Bone Growth
Anthony Wynshaw‐Boris, Fen Zhou, Ann Kuo et al. · Cell · 1996 · 1.1K citations · Full text
Achondroplasia is defined by recurrent G380R mutations of FGFR3.
Gary A. Bellus, Timothy Hefferon, Rosa Isela Ortiz De Luna et al. · PubMed · 1995 · 483 citations